Modifying risk for extracorporeal circulation: Trial of four antiinflammatory strategies

Annals of Thoracic Surgery

Volumn 66, Issue 3, 1998, Pages 747-753

  Gott, John Parker ^a,b   Cooper, William A ^a   Schmidt Jr , Frank E ^a   Brown III, W Morris ^a   Wright, Carolyn E ^a   Merlino, John D ^a   Fortenberry, James D ^a   Clark, W Scott ^a   Guyton, Robert A ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; APROTININ; BLOOD CLOTTING FACTOR 12; CD11 ANTIGEN; CD18 ANTIGEN; COMPLEMENT; CREATININE; HAPTOGLOBIN; HEMOGLOBIN; HEPARIN; LEUKOCYTE ELASTASE; METHYLPREDNISOLONE;

AORTA CLAMPING; AORTA SURGERY; ARTICLE; BLOOD PUMP; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CELL SEPARATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; ECONOMIC EVALUATION; EXTRACORPOREAL CIRCULATION; EXTRACORPOREAL OXYGENATION; FIBRINOLYSIS; HEART SURGERY; HEART VALVE SURGERY; HOSPITAL COST; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; RISK MANAGEMENT;

EID: 0032167537     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00695-X     Document Type: Article

References (24)

1. 1. Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg 1991;51:529-31.
2. 2. Levy JH, Pifarré R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
3. 3. Murkin JM. Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997;11(Suppl 1):19-23.
4. 4. Bando K, Pillai R, Cameron DE, et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:873-7.
5. 5. Gu YJ, deVries AJ, Boonstra PW, van Oeveren W. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg 1996;112:494-500.
6. 6. Hill G, Alonso A, Spurzem J, Stammers, Robbins R. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovase Surg 1995;110:1658-62.
7. 7. Thorn GW. Clinical considerations in the use of corticosteroids. Special Article. N Engl J Med 1996;274:775-81.
8. 8. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate allergic reactions to intravenous contrast material. N Engl J Med 1987;317:845-9.
9. 9. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a randomized double-blind, placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
10. 10. Bidstrup BP, Underwood SR, Sapford RN. Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-53.
11. 11. Murphy PJ, Connery C, Hicks GL Jr, Blumberg N. Homologous blood transfusion as a risk factor for postoperative infection after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1992;104:1092-9.
12. 12. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348:841-5.
13. 13. Blumberg N, Triulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfusion Medicine Reviews 1990;4(suppl 1):24-35.
14. 14. Pearl JM, Drinkwater DC, Laks H, Capouya ER, Gates RN. Leukocyte-depleted reperfusion of transplanted human hearts: a randomized, double-blind clinical trial. J Heart Lung Transplant 1992;11:1082-92.
15. 15. Byrne JG, Appleyard RF, Lee CC, et al. Controlled reperfusion of the regionally ischemic myocardium with leukocyte-depleted blood reduces stunning, the no-reflow phenomenon, and infarct size. J Thorac Cardiovasc Surg 1992;103: 66-72.
16. 16. Sawa Y, Matsuda H, Shimazaki Y, et al. Evaluation of leukocyte-depleted terminal blood cardioplegic solution in patients undergoing elective and emergency coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;108:1125-31.
17. 17. Wilson IC, Gardner TJ, DiNatale JM, Gillinov AM, Curtis WE, Cameron DE. Temporary leukocyte depletion reduces ventricular dysfunction during prolonged postischemic reperfusion. J Thorac Cardiovasc Surg 1993;106:805-10.
18. 18. Lazar HL, Zhang X, Hamasaki T, et al. Role of leukocyte depletion during cardiopulmonary bypass and cardioplegic arrest. Ann Thorac Surg 1995;60:1745-8.
19. 19. Johnson D, Thomson D, Mycyk T, Burbridge B, Mayers I. Depletion of neutrophils by filter during aortocoronary bypass surgery transiently improves postoperative cardiorespiratory status. Chest 1995;107:1253-9.
20. 20. Jones DR, Hill RC, Hollingsed MJ, et al. Use of heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1993;56: 566-8.
21. 21. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-22.
22. 22. Redmond JM, Gillinov AM, Stuart RS, et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 1993;56:474-9.
23. 23. Wagner WR, Johnson PC, Thompson KA, Marrone GC. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg 1994;58:734-41.
24. 24. Edmonds LH Jr. Surface-bound heparin - panacea or peril? [Editorial]. Ann Thorac Surg 1994;58:285-6.